Terms: = Breast cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM
609 results:
1. The Flourishing Scale: Psychometric Properties in breast cancer Patients.
Cerezo MV; Soria-Reyes LM; Alarcón R; Blanca MJ
Integr Cancer Ther; 2024; 23():15347354241249935. PubMed ID: 38755965
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in cancer.
Shreenivas A; Nishizaki D; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Kato S; Kurzrock R
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731962
[TBL] [Abstract] [Full Text] [Related]
3. Application of Patient-Reported Outcome Measurements in Adult Tumor Clinical Trials in China: Cross-Sectional Study.
Jia Y; Li Q; Zhang X; Yan Y; Yan S; Li S; Li W; Wu X; Rong H; Liu J
J Med Internet Res; 2024 May; 26():e45719. PubMed ID: 38718388
[TBL] [Abstract] [Full Text] [Related]
4. Is the QCI framework suited for monitoring outcomes and costs in a teaching hospital using value-based healthcare principles? A retrospective cohort study.
van Veghel W; van Dijk SC; Klem TM; Weel AE; Bügel JB; Birnie E
BMJ Open; 2024 May; 14(5):e080257. PubMed ID: 38692726
[TBL] [Abstract] [Full Text] [Related]
5. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
6. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
7. Non-medical interventions to enhance return to work for people with cancer.
de Boer AG; Tamminga SJ; Boschman JS; Hoving JL
Cochrane Database Syst Rev; 2024 Mar; 3(3):CD007569. PubMed ID: 38441440
[TBL] [Abstract] [Full Text] [Related]
8. Hyperthyroidism and the risk of non-thyroid cancer: a Danish register-based long-term follow-up study.
Riis T; Bonnema SJ; Brix TH; Folkestad L
Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38367342
[TBL] [Abstract] [Full Text] [Related]
9. Design, Synthesis and In-Silico Studies of Piperidine-Dihydropyridine Hybrids as Anticancer Agents.
Rejinthala S; Endoori S; Thumma V; Mondal T
Chem Biodivers; 2024 Apr; 21(4):e202301456. PubMed ID: 38366873
[TBL] [Abstract] [Full Text] [Related]
10. Prognosis prediction and risk stratification of breast cancer patients based on a mitochondria-related gene signature.
Wang Y; Wang DY; Bu KN; Gao JD; Zhang BL
Sci Rep; 2024 Feb; 14(1):2859. PubMed ID: 38310106
[TBL] [Abstract] [Full Text] [Related]
11. breast cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status.
Xu S; Murtagh S; Han Y; Wan F; Toriola AT
JAMA Netw Open; 2024 Jan; 7(1):e2353331. PubMed ID: 38277147
[TBL] [Abstract] [Full Text] [Related]
12. Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: a two-center study of 1,170 patients.
Qu F; Luo Y; Peng Y; Yu H; Sun L; Liu S; Zeng X
Front Immunol; 2023; 14():1335546. PubMed ID: 38274836
[TBL] [Abstract] [Full Text] [Related]
13. Patient survey on cancer genomic medicine in Japan under the national health insurance system.
Kage H; Akiyama N; Chang H; Shinozaki-Ushiku A; Ka M; Kawata J; Muto M; Okuma Y; Okita N; Tsuchihara K; Kikuchi J; Shirota H; Hayashi H; Kokuryo T; Yachida S; Hirasawa A; Kubo M; Kenmotsu H; Tanabe M; Ushiku T; Muto K; Seto Y; Oda K
Cancer Sci; 2024 Mar; 115(3):954-962. PubMed ID: 38273803
[TBL] [Abstract] [Full Text] [Related]
14. Multiparametric MRI model to predict molecular subtypes of breast cancer using Shapley additive explanations interpretability analysis.
Huang Y; Wang X; Cao Y; Li M; Li L; Chen H; Tang S; Lan X; Jiang F; Zhang J
Diagn Interv Imaging; 2024 May; 105(5):191-205. PubMed ID: 38272773
[TBL] [Abstract] [Full Text] [Related]
15. Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer.
Li X; Zhang Y; Zhu C; Xu W; Hu X; Martínez DAS; Romero JLA; Yan M; Dai Y; Wang H
BMC Womens Health; 2024 Jan; 24(1):38. PubMed ID: 38218823
[TBL] [Abstract] [Full Text] [Related]
16. Dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: Real-world data from a developing country.
Sharma RK; Gogia A; Deo S; Sharma D; Mathur S; Sagiraju HKR
Indian J Cancer; 2023 Oct; 60(4):505-511. PubMed ID: 38189648
[TBL] [Abstract] [Full Text] [Related]
17. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human cancers: A Scoping Review.
Lozar T; Wang W; Gavrielatou N; Christensen L; Lambert PF; Harari PM; Rimm DL; Burtness B; Grasic Kuhar C; Carchman EH
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140561
[TBL] [Abstract] [Full Text] [Related]
18. Survivorship care in breast cancer: understanding implementation barriers through the lens of the Theoretical Domains Framework.
Brauer ER; Petersen L; Ganz PA
JNCI Cancer Spectr; 2024 Jan; 8(1):. PubMed ID: 38128018
[TBL] [Abstract] [Full Text] [Related]
19. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
Dai X; Shi X; Luo M; Li P; Gao Y
BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
[TBL] [Abstract] [Full Text] [Related]
20. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Cescon DW; Schmid P; Rugo HS; Im SA; Md Yusof M; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Haiderali A; Zhou X; Guo Z; Nguyen AM; Cortes J
J Natl Cancer Inst; 2024 May; 116(5):717-727. PubMed ID: 38070159
[TBL] [Abstract] [Full Text] [Related]
[Next]
